<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02698839</url>
  </required_header>
  <id_info>
    <org_study_id>PIONEER-II, RCT, P01</org_study_id>
    <nct_id>NCT02698839</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)</brief_title>
  <acronym>RCT</acronym>
  <official_title>A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients With de Novo Coronary Lesions, RCT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sino Medical Sciences Technology Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sino Medical Sciences Technology Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PIONEER-II RCT trial is a prospective, multicenter, randomized, non-inferiority registry
      trial. 539 subjects from about 40 interventional cardiology centers in China will be enrolled
      to evaluate In-stent late lumen loss(LLL) as the primary endpoint at 9 months. And all the
      subjects will be followed up to 5 years to attain the data of the secondary endpoints.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Realizing even more uniform and complete endothelial coverage, BuMA Supreme™ biodegradable
      drug coating coronary stent system comprises a new generation of biodegradable drug eluting
      stent under development by SINOMED. BuMA Supreme™ reconfigures BuMA™ DES utilizing a high
      caliber cobalt chromium platform coated with rapidly degrading PLGA scaffold.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>in-stent Late Lumen Loss, 9M</measure>
    <time_frame>QCA at 9-month follow-up window</time_frame>
    <description>The primary endpoint is in-stent Late Lumen Loss (LLL) at 9-month after stent implantation as assessed by off-line quantitative coronary angiography (QCA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent implantation success rate</measure>
    <time_frame>5 years after PCI</time_frame>
    <description>The stent implantation success rate includes device success, lesion success and clinical success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis rate</measure>
    <time_frame>9 months</time_frame>
    <description>Binary restenosis was defined in every segment (proximal, distal, and stent) as a &gt;50% diameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in-segment LLL</measure>
    <time_frame>9 months</time_frame>
    <description>to evaluate the in-sigment Late Lumen Loss (LLL) at 9-month after stent implantation as assessed by off-line quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diameter stenosis degree</measure>
    <time_frame>9 months</time_frame>
    <description>to compare the lumen diameter at 9-month after stent implantation with the baseline diameter as assessed by off-line quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-oriented Composite Endpoint (DoCE)</measure>
    <time_frame>1, 6, 12 month, and annually up to 5 years post procedure</time_frame>
    <description>Device-oriented Composite Endpoint is defined as cardiac death, target vessel MI, or clinically-driven target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented Composite Endpoint (PoCE)</measure>
    <time_frame>1, 6, 12 month, and annually up to 5 years post procedure</time_frame>
    <description>Patient-oriented Composite Endpoint is defined as all cause death, all myocardial ischemia (MI), or any revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Academic Research Consortium(ARC) defined stent thrombosis</measure>
    <time_frame>5 years after PCI</time_frame>
    <description>Definite and probable stent thrombosis during acute, subacute, later and very late phase.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">539</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>BuMA Supreme group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group contains 319 subjects. Among them, 220 subjects will be implanted with regular specifications and 99 subjects with narrower, wider or longer ones.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BuMA™ group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group contains 220 subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BuMA Supreme</intervention_name>
    <description>Stent platform: cobalt-chromium alloy</description>
    <arm_group_label>BuMA Supreme group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BuMA™</intervention_name>
    <description>Stent platform: stainless steel</description>
    <arm_group_label>BuMA™ group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-75, male or non-pregnant female

          2. Evidence of non-symptomatic ischemia, stable or non-stable angina pectoris or past MI

          3. Target lesion is primary and de-novo coronary artery disease

          4. The target lesion length ≤ 60 mm, diameter 2.25mm－5.0mm (visually estimated)

          5. Lesion diameter stenosis ≥70% (visually estimated)

          6. For each target lesion, same stent implantation only

          7. Acceptable candidate for coronary artery bypass grafting (CABG)

          8. Understand the study purpose, willing to participate and sign the letter of consent,
             agrees to the follow-up visits including a 9 month angiographic follow-up

        Exclusion Criteria:

          1. Acute MI within 1 week

          2. Chronic total occlusion(TIMI 0), left main lesion, intervention-required three-vessel
             lesions, branch vessel diameter ≥ 2.5mm and bypass lesion

          3. More than 3 stents required

          4. Patients refuse to be implanted stent

          5. Calcified lesion failed in pre-dilation, twisted lesion and lesion unsuitable for
             stent delivery and expansion

          6. In-stent restenosis

          7. Planned percutaneous coronary intervention (PCI) within 3 months post procedure

          8. Other stents implanted within 1 year

          9. Severe heart failure (NYHA above III) or left ventricle ejection fraction (EF) &lt;40%

         10. Renal function damage, blood creatinine &gt; 176.82 μmol/L

         11. Bleeding tendency, active peptic ulcer disease, cerebral or subarachnoid hemorrhage,
             cerebral apoplexy within half year and contraindication for any anti-platelet or
             anticoagulation agents

         12. Allergic to drugs or agents used in stent or protocol (PLGA, sirolimus, aspirin,
             clopidogrel, contrast agent, cobalt, nickel, chromium, iron, wolfram et. al.)

         13. Life expectation &lt; 12 months

         14. Have not reached the primary end point when participating in other trial

         15. Poor compliance to the protocol

         16. Heart implantation cases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yundai Chen, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The General Hospital of PLA (301 hospital)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shaoping Nie, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bejing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shubin Qiao, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fu Wai Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yawei Xu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai 10th People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Yu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The 2th Affiliated Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junbo Ge, Ph.D.</last_name>
    <phone>+86-021-64041990</phone>
    <phone_ext>2745</phone_ext>
    <email>ge.junbo@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lei Ge, Ph.D.</last_name>
    <phone>13816112695</phone>
    <email>ge.lei@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junbo Ge, Ph.D</last_name>
      <phone>+86-021-64041990</phone>
      <phone_ext>2745</phone_ext>
      <email>ge.junbo@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2016</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug eluting stents</keyword>
  <keyword>Interventional Cardiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

